title: Hashimoto's encephalopathy after interferon therapy for hepatitis C virus in adult liver transplant recipient accompanied by post-transplant lymphoproliferative disorder related to Epstein-Barr virus infection.
abstract: A 55-year-old woman underwent living-donor liver transplantation (LDLT). She had no history of autoimmune diseases. Spleen was preserved. Steroids were withdrawn at 3 months after LDLT. Epstein-Barr virus (EBV) infection occurred at 3.5 years after LDLT. Recurrent hepatitis C virus infection was confirmed at 4.5 years after LDLT, and pegylated interferon was introduced. Diagnosis of EBV-positive post-transplant lymphoproliferative disorder (PTLD) was made at 4.8 years after LDLT, and tacrolimus (Tac) was stopped completely. Then, unconsciousness, convulsion, and cervical stiffness appeared suddenly. Electroencephalography, cerebrospinal fluid analysis, and image studies revealed normal or only nonspecific findings. The patient was in a state of exhaustion; therefore, steroid pulse therapy (SPT) was attempted. Surprisingly, her general condition, including consciousness disturbance, was improved markedly, and Hashimoto's encephalopathy (HE) was suspected, based on this reaction to SPT. Elevations of anti-thyroglobulin antibody and anti-thyroid peroxidase antibody were confirmed. After withdrawal of Tac, and treatment with acyclovir and steroids, EBV-positive PTLD and HE improved, although they recurred at 5.1 years after LDLT. SPT improved only neurological symptoms. Molecular-targeted therapy was given for recurrent PTLD, based on analysis of sampling specimens. This therapy was effective, but tumor lysis syndrome occurred, and the patient died at 5.3 years after LDLT.
authors.affiliation: Department of Transplant Surgery, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan. horit@kuhp.kyoto-u.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Hori
authors.forename: F
authors.initials: F
authors.lastname: Oike
authors.forename: K
authors.initials: K
authors.lastname: Hata
authors.forename: M
authors.initials: M
authors.lastname: Nishikiori
authors.forename: Y
authors.initials: Y
authors.lastname: Ogura
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: Y
authors.initials: Y
authors.lastname: Takada
authors.forename: H
authors.initials: H
authors.lastname: Egawa
authors.forename: J H
authors.initials: JH
authors.lastname: Nguyen
authors.forename: S
authors.initials: S
authors.lastname: Uemoto
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D001927:Brain Diseases / Q000150:complications / Q000175:diagnosis; D004359:Drug Therapy, Combination; D004660:Encephalitis; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000821:virology*; D005260:Female; D050031:Hashimoto Disease / Q000150:complications / Q000175:diagnosis; D016174:Hepacivirus / Q000187:drug effects; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000150:complications* / Q000821:virology; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons